Cancer care Insight Report

MRD's Green Decision Gap: Why Oncologists Trust the Signal, But Hesitate to Act

A peer-level look at how oncology professionals are using measurable residual disease today, where it feels clinically useful, and why the hardest question is no longer detection alone, but when to act.

Healthcare professionals: 73 responses

Complete responses: 59

Countries: 6

Survey ID: 8813056

– headline finding

0 %

describe MRD as either a decisive tool or a useful clinical signal, yet the survey shows that actionability remains conditional.

see at least moderate overreaction risk

0 %

say evidence for acting is unclear when signals conflict

0 %

see MRD as essential only in defined scenarios

0 %

cite unclear thresholds as the uncomfortable reality

0 %

– Quick Read — Key Findings

01 // Practice Role

🧬

38.3%

Useful signal, not usually decisive

The largest group values MRD, but does not treat it as the single deciding factor.

02 // Clinical Home

🩸

36.7%

Most influence in hematologic malignancies

MRD remains strongest where disease markers and monitoring logic are more established.

03 // Evidence Gap

⚖️

47.5%

Concern without clear action evidence

When MRD and conventional indicators diverge, uncertainty often enters the decision.

04 // Overreaction Risk

🛑

71.2%

High or moderate overreaction risk

Clinicians value early detection, but many remain alert to overtreatment and anxiety.

05 // Action Threshold

📏

32.2%

Lack clear thresholds

The threshold problem is the strongest uncomfortable reality in current MRD use.

06 // Treatment Escalation

💊

42.4%

Escalates only in selected cases

MRD nudges action, but the dominant pattern is selective rather than routine escalation.

07 // Future Role

🔬

45.8%

Essential in defined scenarios

The future looks important, but narrower and more disease-specific than broad hype suggests.

Ready for the full clinical interpretation?

Download the complete report with the executive summary, data interpretation, clinical implications, qualitative response themes, references, and backend-ready tables.

Background & Methodology

Why we asked oncologists about MRD now

MRD can identify residual disease that conventional methods may not detect. In oncology practice, this creates both an opportunity and a dilemma: clinicians may see risk earlier, but earlier detection does not always create a standardized treatment action.

MDForLives reviewed responses from 73 oncology survey participants, including 59 complete and 14 partial responses. The analysis uses question-level denominators of n=59 or n=60 because partial responses were included for some earlier questions.

MRD has crossed the adoption threshold, but not the actionability threshold. The signal is valued, yet its clinical meaning still depends on context.

MDForLives Research Interpretation

Core Finding

The adoption paradox: trusted signal, conditional action

The survey shows that MRD is not peripheral. 33.3% describe it as a decisive tool, while 38.3% call it a useful signal that is rarely the deciding factor. Together, 71.6% assign MRD a meaningful role in practice.

decisive tool

0 %

useful but rarely decisive

0 %

additional complexity

0 %

not yet relevant

0 %

71.6%

describe MRD as clinically meaningful, but the larger pattern points to conditional use rather than automatic MRD-led decision-making.

Clinical Setting

Why hematologic malignancies still anchor MRD practice

MRD’s influence is strongest where disease monitoring frameworks are clearer and where molecular or cellular assessment is more established.

The concentration in hematologic malignancies and post-treatment surveillance suggests that clinicians are most comfortable with MRD in settings where ongoing monitoring has a clearer clinical logic. Early-stage solid tumors and treatment escalation or de-escalation remain more cautious territories.

Interpretation Gap

The same MRD result may not lead to the same decision

Interpretation consistency appears split. This may be one of the hidden barriers to broader MRD implementation.

highly or mostly consistent interpretation

0 %

variability, inconsistency, or no consensus

0 %

evidence unclear when MRD conflicts with conventional indicators

0 %

both signals require subjective judgment

0 %

MRD’s implementation challenge is not simply availability. It is whether clinicians can interpret test results with enough shared clarity to decide when a molecular signal should change treatment, when it should intensify surveillance, and when it should be held in context.

Threshold Problem

The uncomfortable reality is not detection. It is what counts as meaningful change.

The leading discomfort is lack of clear thresholds, followed by concern that clinicians may detect disease earlier than they know how to act on it.

This is the core decision gap. Greater sensitivity may improve risk awareness, but without disease-specific thresholds and action rules, earlier detection can create more questions than answers.

Overreaction Risk

Clinicians value MRD, but many fear acting too quickly

A majority see at least moderate risk that MRD signals may trigger unnecessary treatment changes if not carefully contextualized.

The concern is not anti-MRD. It is pro-context. The open-text responses repeatedly mention what would be lost without MRD: early detection, response assessment, recurrence tracking, and objective monitoring. The same comments also mention what might be avoided: overtreatment, confusion, false relapse concerns, costs, and molecular anxiety.

Escalation Discipline

MRD is nudging earlier intervention, but mostly in selected cases

MRD affects treatment intensity for many clinicians, but most do not describe routine aggressive escalation.

The largest group, 42.4%, says MRD pushes earlier or more aggressive intervention only occasionally in selected cases. That suggests a disciplined clinical pattern: MRD informs timing, but treatment escalation still requires a stronger alignment of disease context, patient risk, and evidence.

Future Role

The future of MRD looks essential, but tightly defined

The strongest future expectation is not universal MRD-driven care. It is careful integration in defined scenarios.

Only 15.3% believe MRD will redefine treatment decision-making across cancers. The larger view is more disciplined: 45.8% expect MRD to become essential only in tightly defined scenarios, and 32.2% expect it to remain complementary rather than a driver.

//Methodology

How this research was read

Total responses

Complete responses

Completion rate

0 %

Countries represented

This insight summary is based on MDForLives survey SGID 8813056. Percentages are reported as shown in the source survey output. Some totals may not sum exactly to 100.0% due to rounding.

// at a glance

Total Survey Records

Countries Covered

Specialty

Oncologists

Published Date

2026

Completion Rate

80.8%

Survey ID

8813056